OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study

Clinical Trial ID NCT00134160

PubWeight™ 14.90^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00134160

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone.	Kidney Int	2012	4.53
2	Blood pressure control for diabetic retinopathy.	Cochrane Database Syst Rev	2015	2.19
3	Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.	Am J Med	2012	1.76
4	Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).	Hypertens Res	2009	0.97
5	Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.	Vasc Health Risk Manag	2012	0.81
6	Role of olmesartan in combination therapy in blood pressure control and vascular function.	Vasc Health Risk Manag	2010	0.79
7	Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study.	Hypertens Res	2014	0.79
8	Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: subanalysis of the OSCAR study.	Hypertens Res	2014	0.79
9	Cardio classics revisited: focus on the role of amlodipine.	Integr Blood Press Control	2012	0.77
10	Reappraisal of role of angiotensin receptor blockers in cardiovascular protection.	Vasc Health Risk Manag	2011	0.77
11	Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness.	Clin Pharmacol	2015	0.75